PathoQuest

company

About

PathoQuest is a biotech company developing NGS-based metagenomic tests for exhaustive identification of pathogens.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
€15M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2011
Number Of Employee
11 - 50
Operating Status
Active

PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurance managers/production managers.

PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.

PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€23M
PathoQuest has raised a total of €23M in funding over 2 rounds. Their latest funding was raised on Nov 9, 2021 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 9, 2021 Series B €15M 1 Detail
Sep 6, 2019 Series Unknown €8M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
PathoQuest is funded by 1 investors. Verve Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Verve Ventures Series B